

LabPad® Evolution

POINT OF CARE



Multi-technology
Multi-parameters
Point of Care device



- *Two technologies in a single device for a unique evolutive panel of tests:*
 - Tsmart® INR
 - Ksmart® SARS-COV2 Antigen
 - Ksmart® SARS-COV2 Antibody
 - Additional Cardiac, Sepsis and Nutrition parameters coming soon
- *Designed to adapt to your practice*
 - Worry free traceability and connectivity to your smartphone and LIS
- *An innovative and efficient solution*
 - A unique patented technology

Ksmart® SARS-COV2 Antigen

The Ksmart® SARS-COV2 Antigen Test System is a rapid immunochromatographic test for the qualitative detection of SARS-CoV-2 antigens in nasopharyngeal swabs.

**Automated reading
and interpretation eliminates
inter-operator variability**

- Results available within 5 to 20 minutes.
- Full connectivity for results processing.

RESULTS IN THREE STEPS

K SMART®



Features

Sample	Nasopharyngeal swab
Test time	5-20 minutes for positive test 20 minutes for negative test
kit content	Ksmart® SARS-COV2 Antigen: 25 Nasopharyngeal sterile swab: 25 Antigen extraction tube: 25 Antigen extract buffer: 2
Shelf life	12 months
Storage	4-30°C / 39.2-86 °F

Performance

		PCR Test		Total
		Positive	Negative	
Ksmart® SARS-COV2 Antigen	Positive	164	3	167
	Negative	12	438	450
	Total	176	441	617

Sensitivity : 93.18%
Specificity : 99.32%

Performances were confirmed in a randomized prospective study performed in France in real life conditions.

Details available upon request.



Why perform an antigen test? ---

To diagnose a SARS-CoV-2 infection, whether symptomatic or asymptomatic:

- Take appropriate sanitary measures to contain the spread of the virus.
- Justify a «Negative Test» to travel or to attend cultural or sporting events.

Why do a serological test? ---

Check the immunity status of patients, who may have developed asymptomatic infection since the start of the pandemic:

- In certain cases a single dose of vaccine is sufficient for these patients.
- Vaccine doses and vaccination slots will be freed up and will improve the vaccination coverage.

Why choose a quantitative test targeting anti-S IgG antibodies? ---

- Anti-protein S antibodies are more relevant than anti-protein N antibodies in identifying a previous infection.
- All the vaccines available in Europe induce the immune system to produce S protein, and therefore antibodies directed against this protein. A test targeting these antibodies makes it possible to evaluate the immune response level to vaccination, and a quantitative result allows longterm monitoring of post-vaccination immune responses.

Ksmart[®] SARS-COV2 Antibody IgG/IgM

The Ksmart[®] SARS-COV2 Antibody IgG/IgM Test System is a rapid immunochromatographic test for the quantitative detection of IgG and the qualitative detection of IgM anti-S antibodies to SARS-CoV-2 in whole blood or serum samples. Which enables detection of primary infections as well as longterm monitoring of immune response.

**Automated reading
and interpretation eliminates
inter-operator variability**

- Results available in 20 minutes.
- Quantitative IgG result for longterm monitoring of the post-vaccination immune response.
- Connectivity for results processing.

RESULTS IN THREE STEPS

K SMART[®]




Features

Sample	Capillary Whole Blood Serum
Test time	20 minutes
Results:	For IgG from 2 to 100 AU (Abitrary Unit) For IgM positive or negative
Kit content	Ksmart [®] SARS-COV-2 Antibody IgG/IgM: 25
Pipette 20 µL	25
Dilution buffer	1
Shelf life	12 months
Storage	4-30°C / 39,2-86°F

Performance

	Sensitivity vs RT-PCR	Specificity vs RT-PCR
Ksmart [®] SARS-COV-2 IgG	94.91%	99.75%
Ksmart [®] SARS-COV-2 IgM	84.55%	98.05%

Post-vaccination control of the immune response



Tsmart® INR

The Tsmart® INR measurement system allows you to monitor your patients undergoing anti-vitamin K (AVK) anticoagulant treatment, and adapts perfectly to your medical practices as close as possible to the patients.

Ergonomic

- 3µL of capillary whole blood.
- 3D shape for easy handling.
- Built-in Datamatrix for automatic reading of batch calibration.
- Non-contact microcuvette ejection for operator safety.

Reliable




- Optical detection technique with excellent correlation to laboratory instruments.
- Individually packaged to ensure stability of the reagent.
- Pre and post-analytical optical self-checks.
- 2 QC levels available.

RESULTS IN THREE STEPS

SMART®




Patented microfluidique technology




Features

Sample	3µL capillary whole blood
Test time	<1 minute
Range of results	INR 0.8-8 PT 7.2-72 secondes QT 10-110 %
LQC	2 levels
Kit content	12, 24 or 48 Tsmart® INR microcuvettes
Shelf life	18 months
Storage	15-25°C / 59-77 °F

Performance



Initial clinical validation study performed in Grenoble University Hospital.



Multiples additional studies conducted in real-life routine conditions confirmed excellent performances.

Details available upon request.

LABPAD[®] EVOLUTION



THE RESULTS YOU NEED WHEN IT MATTERS MOST

An evolving panel of POC tests

Available

- Tsmart[®] INR (coagulation)
- Ksmart[®] SARS-COV2 Antigen
- Ksmart[®] SARS-COV-2 Antibody

Coming soon

- Cardiac markers
- Sepsis
- Nutrition

Connectivity that fits your needs



Mobile App

- Patient information
- Result transfers



LabPad[®]

- Test execution



Laboratory information system

- Result management and validation

Features

Consumables	Ksmart [®] and Tsmart [®] Touchless ejection preventing contamination
Memory	1000 results
Connectivity	Bluetooth Low Energy USB B port
Power input	Built-in battery with charger
Operating conditions	15 - 32°C / 59 - 90°F
Size	L: 17.2 cm / W: 7.4 cm H: 2 to 4.6 cm
Weight	270 g



LabPad[®] INR
also available

Manufacturer: AVALUN SAS (France)

In vitro diagnostic medical devices.

Read the instructions in the data sheets carefully.

BIO SYNEX

Distributed by: BIOSYNEX S.A.

22 Boulevard Sébastien Brant

67400 ILLKIRCH-GRAFFENSTADEN - France

Phone: 03 88 78 80 88 - Fax: 03 88 78 76 78

E-mail : export@biosynex.com

www.biosynex.com

FLY_LAPPAD_EN_V01202109R01
Rev : 09/21